A nerve pain pill long sold as a “safer” alternative is now tied to higher dementia risk, especially in adults who are still years away from Medicare.
Story Snapshot
- Gabapentin, a widely used nerve pain drug, is linked in new studies to higher rates of dementia and mild cognitive impairment, with the strongest signals in adults under 65.
- Risk rises with heavier use: people with six or more prescriptions had about 29% higher dementia risk and 85% higher mild cognitive impairment risk over ten years.
- A large Taiwan database study also found about a 45% higher dementia risk in people using gabapentin or pregabalin, again with higher risk at higher total doses.
- Another recent study, however, did not find extra dementia risk across dose levels, and experts warn that observational data cannot yet prove gabapentin directly causes dementia.
A “safer” pain pill now under the dementia microscope
Gabapentin was introduced in the 1990s to treat seizures but has since become a go-to pill for nerve pain, chronic back pain, and many off-label uses. Doctors often pitch it as “safer” than opioids, so millions of Americans take it long term, including younger workers trying to stay on the job despite pain. Now a large study of more than 26,000 adults with chronic low back pain has found that people with six or more gabapentin prescriptions were more likely to be diagnosed with dementia or mild cognitive impairment within ten years.
Researchers in that study reviewed medical records from dozens of U.S. health systems and compared adults with chronic back pain who did and did not receive gabapentin. Those who had six or more prescriptions were about 29 percent more likely to develop dementia and 85 percent more likely to develop mild cognitive impairment than similar patients who never took the drug. The risk climbed further with heavier use: people who received twelve or more prescriptions had about 40 percent higher dementia risk and 65 percent higher mild cognitive impairment risk compared to those with three to eleven prescriptions.
Younger adults show the strongest risk signal
One of the most disturbing details for families is that the dementia signal was not limited to seniors. When researchers broke down the numbers by age, adults between 18 and 64 who were prescribed gabapentin had more than double the risk of being diagnosed with dementia or mild cognitive impairment compared with similar adults who did not use the drug. The risk was even higher for people aged 35 to 64, where dementia chances more than doubled and mild cognitive impairment risk more than tripled in some analyses.
Those findings cut against the common belief that dementia is mainly a problem for people over 70. They raise a stark question: are millions of younger workers and caregivers trading today’s pain relief for tomorrow’s memory loss? Many Americans already feel the system pushes quick-fix pills instead of fixing root causes of pain. Seeing a “safer” non-opioid drug tied to brain decline feeds the wider fear that health decisions are driven more by drug marketing and insurance rules than by long-term brain health.
Other studies support a link, but one shows no extra risk
The low back pain study is not the only warning sign. A national health insurance database study from Taiwan tracked more than 200,000 adults and found that people who used gabapentin or the related drug pregabalin had about a 45 percent higher risk of developing dementia than matched non-users. Again, risk went up with higher total doses over time, pointing to a possible dose-response pattern that worries many neurologists and geriatric doctors.
A recent meta-analysis that pooled five observational studies covering over 325,000 participants found that use of gabapentinoid drugs was associated with modestly higher odds of Alzheimer’s disease–related dementia, with an odds ratio around 1.28. However, the authors noted very high differences across studies and warned about confounding factors, such as the fact that people needing long-term nerve pain drugs may already have more health problems that raise dementia risk. Importantly, another study of adults on long-term gabapentin for chronic pain did not find a higher adjusted risk of dementia or a clear dose-response pattern after careful control for age, other illnesses, and other medications.
Experts urge caution, not panic, as evidence remains observational
Specialists who reviewed the new data say the studies show an association but do not prove that gabapentin directly causes dementia. These are retrospective observational studies, meaning researchers looked back at past records rather than randomly assigning people to take or avoid the drug. That design makes it hard to fully separate the effects of the drug from the effects of chronic pain, depression, sleep problems, or other conditions that themselves can harm thinking over time.
Still, the pattern is strong enough that many experts now advise more cautious prescribing, especially for off-label uses and long-term treatment when other options exist. Some palliative care and geriatric groups already warn that gabapentin can worsen confusion or balance, at least during the first year of therapy. For families already worried about “brain fog” and rising dementia rates, the idea that a widely used pain pill could quietly chip away at memory over a decade fits a broader concern: the health system often reacts to symptoms with more pills while leaving patients to discover long-term tradeoffs on their own.
What this means for patients and a frustrated public
For patients, the key is not to suddenly stop gabapentin without talking to a doctor, since abrupt changes can cause withdrawal symptoms or worse pain. Instead, people who have taken the drug for many months or years, especially those under 65 with numerous prescriptions, may want to ask their clinicians about brain risks, regular cognitive screening, and possible dose reductions or alternative treatments. Families caring for aging parents might also ask whether gabapentin is still needed or whether non-drug options could replace it.
For the wider public, these studies deepen a bipartisan worry that powerful health and drug systems are not fully transparent about long-term risks. Seeing yet another common medication tied to dementia risk through quiet journal articles rather than clear public warnings reinforces the sense that ordinary people must do their own research to protect their brains. The evidence so far does not prove that gabapentin causes dementia, but it does suggest that long-term, high-frequency use is far from risk-free—and that the “safer” label many patients were sold deserves a closer, more honest look.
Sources:
docs.google.com, pubmed.ncbi.nlm.nih.gov, pmc.ncbi.nlm.nih.gov, bmjgroup.com, medscape.com, alzinfo.org, sciencemediacentre.org, connect.mayoclinic.org, reddit.com
